Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Removal of Phosphorus with the Use of Marl and Travertine and Their Thermally Modified Forms-Factors Affecting the Sorption Capacity of Materials and the Kinetics of the Sorption Process.
Gubernat S, Masłoń A, Czarnota J, Koszelnik P, Chutkowski M, Tupaj M, Gumieniak J, Kramek A, Galek T. Gubernat S, et al. Among authors: czarnota j. Materials (Basel). 2023 Jan 31;16(3):1225. doi: 10.3390/ma16031225. Materials (Basel). 2023. PMID: 36770230 Free PMC article.
Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration.
Niezgoda A, Biegański G, Wachowiak J, Czarnota J, Siemionow K, Heydemann A, Ziemiecka A, Sikorska MH, Bożyk K, Siemionow M. Niezgoda A, et al. Among authors: czarnota j. Arch Immunol Ther Exp (Warsz). 2023 Nov 24;71(1):24. doi: 10.1007/s00005-023-00691-y. Arch Immunol Ther Exp (Warsz). 2023. PMID: 37999748 Free PMC article.
Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration.
Siemionow M, Biegański G, Niezgoda A, Wachowiak J, Czarnota J, Siemionow K, Ziemiecka A, Sikorska MH, Bożyk K, Heydemann A. Siemionow M, et al. Among authors: czarnota j. Stem Cell Rev Rep. 2023 Nov;19(8):2724-2740. doi: 10.1007/s12015-023-10620-3. Epub 2023 Sep 14. Stem Cell Rev Rep. 2023. PMID: 37707670 Free PMC article.
Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up.
Heydemann A, Bieganski G, Wachowiak J, Czarnota J, Niezgoda A, Siemionow K, Ziemiecka A, Sikorska MH, Bozyk K, Tullius SG, Siemionow M. Heydemann A, et al. Among authors: czarnota j. Stem Cell Rev Rep. 2023 Jul;19(5):1340-1359. doi: 10.1007/s12015-023-10530-4. Epub 2023 Mar 31. Stem Cell Rev Rep. 2023. PMID: 37000376 Free PMC article.
20 results